PubMed 10 Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S,

PubMed 10. Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H: Expression of ERCC1 and class III [beta]-tubulin in non-small cell lung cancer patients Maraviroc datasheet treated with carboplatin and paclitaxel. Lung Cancer 2009, 64:326–333.PubMedCrossRef 11. Burkhart CA, Kavallaris M, Band Horwitz S: The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001, 1471:O1-O9.PubMed 12. Crino L, Weder W, van Meerbeeck

J, Felip E: Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010,21(Suppl 5):v103-v115.PubMedCrossRef 13. Gossage L, Madhusudan S: Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 2007, 33:565–577.PubMedCrossRef 14. Li J-J, Ding Y, Li D-D, Peng R-Q, Feng G-K, Zeng Y-X, Zhu X-F, Zhang X-S: The overexpression of ERCC-1 is involved in

the resistance of lung cancer cells to cetuximab combined with PD-0332991 mouse DDP. Cancer Biol Ther 2009, 8:1914–1921.PubMedCrossRef 15. Li J, Li ZN, Yu LC, Bao QL, Wu JR, Shi SB, Li XQ: Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer 2010, 69:116–122.PubMedCrossRef 16. Wang X, Zhao J, Yang L, Mao L, An T, Bai H, Wang S, Liu X, Feng G, Wang J: Positive expression of ERCC1 selleck inhibitor predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Medical Oncology 2010, 27:484–490.PubMedCrossRef 17. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Vinolas N, Paz-Ares L, Lopez-Vivanco G, Munoz MA, et al.: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25:2747–2754.PubMedCrossRef

18. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007, 356:800–808.PubMedCrossRef 19. Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, et al.: ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 2008, 60:401–407.PubMedCrossRef 20. Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, Eguchi K, Ochiai A: Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 2009, 64:98–104.PubMedCrossRef 21. Cutress RI, Townsend PA, Brimmell M, Bateman AC, Hague A, Packham G: BAG-1 expression and function in human cancer. Br J Cancer 2002, 87:834–839.PubMedCrossRef 22. Takayama S, Reed JC: Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell Biol 2001, 3:E237-E241.PubMedCrossRef 23.

Comments are closed.